A method for predicting the response of metastases to immunotherapy in a metastatic colorectal cancer patient

A method for determining the response of a metastasis to immunotherapy in a metastatic colorectal cancer patient, said method comprising determining the density of colon-derived T cells, preferably α4β7+ CD8+ T cells in a patient sample, wherein a higher density of said colon-derived T cells, preferably α4β7+ CD8+ T cells in comparison to a control value is indicative that the metastasis of the patient is responsive to immunotherapy.

A pharmaceutical composition comprising an immune-stimulatory agent, preferably a colorectal cancer vaccine and retinoic acid for use in the treatment of a metastatic colorectal cancer in a patient in need thereof.

A kit for determining the response of a metastasis to immunotherapy in a metastatic colorectal cancer patient comprising anti-α4β7 and anti-CD8 antibodies, preferably anti-α4β7, anti-CD8, anti-CD11c and/or anti-CD68 antibodies.

A kit for determining the response of a metastasis to immunotherapy in a metastatic colorectal cancer patient comprising a pair of primers for amplifying at least one gene marker of CD8+ T cells, preferably at least one gene marker of CD8+ T cells and at least one gene marker of α4β7+ cells, more preferably at least one gene marker of CD8+ T, at least one gene marker of dendritic cell and at least one gene marker of macrophages, again more preferably at least one gene marker of CD8+ T cells and at least one gene marker of α4β7+ cells, at least one gene marker of dendritic cell and at least one gene marker of macrophages.